Comparative Pharmacology
Head-to-head clinical analysis: FLUORINE F 18 versus MIRALUMA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUORINE F 18 versus MIRALUMA.
FLUORINE F-18 vs MIRALUMA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorine-18 decays by positron emission, and the emitted positron annihilates with an electron to produce two 511 keV gamma photons. When incorporated into radiopharmaceuticals such as fludeoxyglucose F-18, it accumulates in metabolically active tissues, enabling PET imaging.
MIRALUMA (garadacimab) is a monoclonal antibody that binds to activated factor XII (FXIIa) and inhibits its activity, thereby blocking the contact activation pathway of the coagulation cascade. This prevents the generation of bradykinin, reducing vascular permeability and swelling in hereditary angioedema (HAE).
2-10 mCi (74-370 MBq) intravenous bolus, single administration for PET imaging.
MIRALUMA (mirvetuximab soravtansine) is administered intravenously at 6 mg/kg adjusted ideal body weight (AIBW) once every 3 weeks until disease progression or unacceptable toxicity.
None Documented
None Documented
Physiological half-life is 109.7 minutes (1.83 hours) for fluorine-18 decay by positron emission, with a physical half-life of 109.7 minutes. The biological half-life is dependent on the radiolabeled compound; for [18F]FDG, the effective half-life is approximately 3-4 hours.
20 hours; prolonged to 30-40 hours in renal impairment requiring dose adjustment
Primarily renal; approximately 95% of administered activity is excreted in urine within 6 hours post-injection. Less than 5% is excreted in feces.
90% renal as unchanged drug; 10% biliary/fecal
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical